<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37441066</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Circulating Reelin promotes inflammation and modulates disease activity in acute and long COVID-19 cases.</ArticleTitle><Pagination><StartPage>1185748</StartPage><MedlinePgn>1185748</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1185748</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1185748</ELocationID><Abstract><AbstractText>Thromboembolic complications and excessive inflammation are frequent in severe COVID-19, potentially leading to long COVID. In non-COVID studies, we and others demonstrated that circulating Reelin promotes leukocyte infiltration and thrombosis. Thus, we hypothesized that Reelin participates in endothelial dysfunction and hyperinflammation during COVID-19. We showed that Reelin was increased in COVID-19 patients and correlated with the disease activity. In the severe COVID-19 group, we observed a hyperinflammatory state, as judged by increased concentration of cytokines (IL-1&#x3b1;, IL-4, IL-6, IL-10 and IL-17A), chemokines (IP-10 and MIP-1&#x3b2;), and adhesion markers (E-selectin and ICAM-1). Reelin level was correlated with IL-1&#x3b1;, IL-4, IP-10, MIP-1&#x3b2;, and ICAM-1, suggesting a specific role for Reelin in COVID-19 progression. Furthermore, Reelin and all of the inflammatory markers aforementioned returned to normal in a long COVID cohort, showing that the hyperinflammatory state was resolved. Finally, we tested Reelin inhibition with the anti-Reelin antibody CR-50 in hACE2 transgenic mice infected with SARS-CoV-2. CR-50 prophylactic treatment decreased mortality and disease severity in this model. These results demonstrate a direct proinflammatory function for Reelin in COVID-19 and identify it as a drug target. This work opens translational clinical applications in severe SARS-CoV-2 infection and beyond in auto-inflammatory diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Calvier, Drelich, Hsu, Tseng, Mina, Nath, Kounnas and Herz.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calvier</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas (UT) Southwestern Medical Center, Dallas, TX, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Neurodegeneration Research, UT Southwestern Medical Center, Dallas, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drelich</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Cellular, and Molecular Biology, University of Texas Medical Branch (UTMB) Health, Galveston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Cellular, and Molecular Biology, University of Texas Medical Branch (UTMB) Health, Galveston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chien-Te</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Cellular, and Molecular Biology, University of Texas Medical Branch (UTMB) Health, Galveston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mina</LastName><ForeName>Yair</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nath</LastName><ForeName>Avindra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kounnas</LastName><ForeName>Maria Z</ForeName><Initials>MZ</Initials><AffiliationInfo><Affiliation>Reelin Therapeutics Inc., San Diego, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herz</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas (UT) Southwestern Medical Center, Dallas, TX, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Neurodegeneration Research, UT Southwestern Medical Center, Dallas, TX, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, UT Southwestern Medical Center, Dallas, TX, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS093382</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 HL063762</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053391</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>126547-89-5</RegistryNumber><NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054407">Chemokine CCL4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054357">Chemokine CXCL10</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018799" MajorTopicYN="N">Intercellular Adhesion Molecule-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054407" MajorTopicYN="N">Chemokine CCL4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054357" MajorTopicYN="N">Chemokine CXCL10</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Reelin</Keyword><Keyword MajorTopicYN="N">adhesion markers</Keyword><Keyword MajorTopicYN="N">cytokine storm</Keyword><Keyword MajorTopicYN="N">endothelial dysfunction</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">leukocyte</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>LC, MK, and JHE are co-shareholders of Reelin Therapeutics, Inc. LC and JHE are co-inventors of a patent related to anti-Reelin strategies application Number: 15/763,047 and Publication Number: 20180273637. MK was employed by the company Reelin Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>13</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>13</Day><Hour>15</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37441066</ArticleId><ArticleId IdType="pmc">PMC10333573</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1185748</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Slater TA, Straw S, Drozd M, Kamalathasan S, Cowley A, Witte KK. Dying &#x2018;due to&#x2019; or &#x2018;with&#x2019; COVID-19: a cause of death analysis in hospitalised patients. Clin Med (2020) 20:e189&#x2013;90. doi:&#xa0;10.7861/clinmed.2020-0440</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0440</ArticleId><ArticleId IdType="pmc">PMC7539724</ArticleId><ArticleId IdType="pubmed">32753516</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Liu Y, Cai X, Zhang W, Li Y, Fu C. Prevalence of venous thromboembolism in critically ill patients with coronavirus disease 2019: a meta-analysis. Front Med (2021) 8:603558. doi:&#xa0;10.3389/fmed.2021.603558</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.603558</ArticleId><ArticleId IdType="pmc">PMC8116594</ArticleId><ArticleId IdType="pubmed">33996843</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#x142;azak W, Drabik L. SARS-CoV-2 infection and SLE: endothelial dysfunction, atherosclerosis, and thrombosis. Clin Rheumatol (2023), 1&#x2013;12. doi:&#xa0;10.1007/s10067-022-06497-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06497-1</ArticleId><ArticleId IdType="pmc">PMC9827021</ArticleId><ArticleId IdType="pubmed">36622519</ArticleId></ArticleIdList></Reference><Reference><Citation>Batah SS, Fabro AT. Pulmonary pathology of ARDS in COVID-19: a pathological review for clinicians. Respir Med (2021) 176:106239. doi:&#xa0;10.1016/j.rmed.2020.106239</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2020.106239</ArticleId><ArticleId IdType="pmc">PMC7674971</ArticleId><ArticleId IdType="pubmed">33246294</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev (2021) 20:102792. doi:&#xa0;10.1016/j.autrev.2021.102792</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond MS, Kanneganti T-D. Innate immunity: the first line of defense against SARS-CoV-2. Nat Immunol (2022) 23:165&#x2013;76. doi:&#xa0;10.1038/s41590-021-01091-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01091-0</ArticleId><ArticleId IdType="pmc">PMC8935980</ArticleId><ArticleId IdType="pubmed">35105981</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki R, Kanneganti T-D. Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. J Transl Med (2022) 20:542. doi:&#xa0;10.1186/s12967-022-03767-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03767-z</ArticleId><ArticleId IdType="pmc">PMC9682745</ArticleId><ArticleId IdType="pubmed">36419185</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauwers M, Au M, Yuan S, Wen C. COVID-19 in joint ageing and osteoarthritis: current status and perspectives. Int J Mol Sci (2022) 23:720. doi:&#xa0;10.3390/ijms23020720</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23020720</ArticleId><ArticleId IdType="pmc">PMC8775477</ArticleId><ArticleId IdType="pubmed">35054906</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr (2021) 15:869&#x2013;75. doi:&#xa0;10.1016/j.dsx.2021.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, et al. . Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep (2021) 36:109518. doi:&#xa0;10.1016/j.celrep.2021.109518</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Spudich S, Nath A. Nervous system consequences of COVID-19. Science (2022) 375:267&#x2013;9. doi:&#xa0;10.1126/science.abm2052</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm2052</ArticleId><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. BMJ (2022) 376:e068993. doi:&#xa0;10.1136/bmj-2021-068993</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068993</ArticleId><ArticleId IdType="pmc">PMC8847881</ArticleId><ArticleId IdType="pubmed">35172971</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med (2022) 28(3):583&#x2013;90. doi:&#xa0;10.1038/s41591-022-01689-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KG-I, Brokstad KA, Zhou F, Linchausen DW, Hansen B-A, et al. . Long COVID in a prospective cohort of home-isolated patients. Nat Med (2021) 27:1607&#x2013;13. doi:&#xa0;10.1038/s41591-021-01433-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander AE, Herz J, Calvier L. Reelin through the years: From brain development to inflammation. Cell Reports (2023). doi:&#xa0;10.1016/j.celrep.2023.112669</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112669</ArticleId><ArticleId IdType="pmc">PMC10592530</ArticleId><ArticleId IdType="pubmed">37339050</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvier L, Alexander AE, Herz J. The &#x201c;6B&#x201d; strategy: Build back a better blood&#x2013;brain barrier. Immuno (2022) 2:506&#x2013;11. doi:&#xa0;10.3390/immuno2030032</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/immuno2030032</ArticleId><ArticleId IdType="pmc">PMC10720986</ArticleId><ArticleId IdType="pubmed">38098699</ArticleId></ArticleIdList></Reference><Reference><Citation>Madonna R, De Caterina R. Relevance of new drug discovery to reduce NF-&#x3ba;B activation in cardiovascular disease. Vasc Pharmacol (2012) 57:41&#x2013;7. doi:&#xa0;10.1016/j.vph.2012.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vph.2012.02.005</ArticleId><ArticleId IdType="pubmed">22366375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y, Huang L, Xian X, Yuhanna IS, Wasser CR, Frotscher M, et al. . Loss of reelin protects against atherosclerosis by reducing leukocyte-endothelial cell adhesion and lesion macrophage accumulation. Sci Signaling (2016) 9:ra29&#x2013;9. doi:&#xa0;10.1126/scisignal.aad5578</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aad5578</ArticleId><ArticleId IdType="pmc">PMC5053773</ArticleId><ArticleId IdType="pubmed">26980442</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvier L, Xian X, Lee RG, Sacharidou A, Mineo C, Shaul PW, et al. . Reelin depletion protects against atherosclerosis by decreasing vascular adhesion of leukocytes. Arterioscler Thromb Vasc Biol (2021) 41:1309&#x2013;18. doi:&#xa0;10.1161/ATVBAHA.121.316000</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.121.316000</ArticleId><ArticleId IdType="pmc">PMC7990715</ArticleId><ArticleId IdType="pubmed">33626909</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvier L, Demuth G, Manouchehri N, Wong C, Sacharidou A, Mineo C, et al. . Reelin depletion protects against autoimmune encephalomyelitis by decreasing vascular adhesion of leukocytes. Sci Transl Med (2020) 12:eaay7675. doi:&#xa0;10.1126/scitranslmed.aay7675</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aay7675</ArticleId><ArticleId IdType="pmc">PMC7860587</ArticleId><ArticleId IdType="pubmed">32801146</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvier L, Manouchehri N, Sacharidou A, Mineo C, Shaul PW, Hui DY, et al. . Apolipoprotein e receptor 2 deficiency decreases endothelial adhesion of monocytes and protects against autoimmune encephalomyelitis. Sci Immunol (2021) 6:eabd0931. doi:&#xa0;10.1126/sciimmunol.abd0931</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd0931</ArticleId><ArticleId IdType="pmc">PMC8627794</ArticleId><ArticleId IdType="pubmed">34452924</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvier L, Herz J, Hansmann G. Interplay of low-density lipoprotein receptors, LRPs, and lipoproteins in pulmonary hypertension. JACC Basic Transl Sci (2022) 7:164&#x2013;80. doi:&#xa0;10.1016/j.jacbts.2021.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacbts.2021.09.011</ArticleId><ArticleId IdType="pmc">PMC8897182</ArticleId><ArticleId IdType="pubmed">35257044</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng W-L, Huang C-L, Chong K-Y, Liao C-H, Stern A, Cheng J-C, et al. . Reelin is a platelet protein and functions as a positive regulator of platelet spreading on fibrinogen. Cell Mol Life Sci (2010) 67:641&#x2013;53. doi:&#xa0;10.1007/s00018-009-0201-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-009-0201-5</ArticleId><ArticleId IdType="pmc">PMC11115871</ArticleId><ArticleId IdType="pubmed">19936619</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng W-L, Chen T-H, Huang C-C, Huang Y-H, Yeh C-F, Tsai H-J, et al. . Impaired thrombin generation in reelin-deficient mice: a potential role of plasma reelin in hemostasis. J Thromb Haemost (2014) 12:2054&#x2013;64. doi:&#xa0;10.1111/jth.12736</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.12736</ArticleId><ArticleId IdType="pubmed">25255925</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowert NS, Kr&#xfc;ger I, Klier M, Donner L, Kipkeew F, Gliem M, et al. . Loss of reelin protects mice against arterial thrombosis by impairing integrin activation and thrombus formation under high shear conditions. Cell Signal (2017) 40:210&#x2013;21. doi:&#xa0;10.1016/j.cellsig.2017.09.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2017.09.016</ArticleId><ArticleId IdType="pubmed">28943410</ArticleId></ArticleIdList></Reference><Reference><Citation>Krueger I, Gremer L, Mangels L, Klier M, Jurk K, Willbold D, et al. . Reelin amplifies GPVI activation and alphaiib Beta3 integrin outside-in signaling via PLC gamma 2 and rho GTPases. Arterioscler Thromb Vasc Biol (2020) 40(10):2391&#x2013;403. doi:&#xa0;10.1161/ATVBAHA.120.314902. ATVBAHA120314902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.314902</ArticleId><ArticleId IdType="pubmed">32787521</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L, Zhao G, Yang Y, Qiu H, Wang L, Kou Z, et al. . A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in middle East respiratory syndrome coronavirus spike protein. J Virol (2014) 88:7045&#x2013;53. doi:&#xa0;10.1128/JVI.00433-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00433-14</ArticleId><ArticleId IdType="pmc">PMC4054355</ArticleId><ArticleId IdType="pubmed">24719424</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvier L, Chouvarine P, Legchenko E, Hoffmann N, Geldner J, Borchert P, et al. . PPAR&#x3b3; links BMP2 and TGF&#x3b2;1 pathways in vascular smooth muscle cells, regulating cell proliferation and glucose metabolism. Cell Metab (2017) 25:1118&#x2013;1134.e7. doi:&#xa0;10.1016/j.cmet.2017.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2017.03.011</ArticleId><ArticleId IdType="pubmed">28467929</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvier L, Boucher P, Herz J, Hansmann G. LRP1 deficiency in vascular SMC leads to pulmonary arterial hypertension that is reversed by PPAR&#x3b3; activation. Circ Res (2019) 124:1778&#x2013;85. doi:&#xa0;10.1161/CIRCRESAHA.119.315088</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.119.315088</ArticleId><ArticleId IdType="pmc">PMC6554044</ArticleId><ArticleId IdType="pubmed">31023188</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvier L, Chouvarine P, Legchenko E, Kokeny G, Mozes MM, Hansmann G. Chronic TGF-&#x3b2;1 signaling in pulmonary arterial hypertension induces sustained canonical Smad3 pathways in vascular smooth muscle cells. Am J Respir Cell Mol Biol (2019) 61:121&#x2013;3. doi:&#xa0;10.1165/rcmb.2018-0275LE</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2018-0275LE</ArticleId><ArticleId IdType="pubmed">31259625</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Arcangelo G, Nakajima K, Miyata T, Ogawa M, Mikoshiba K, Curran T. Reelin is a secreted glycoprotein recognized by the CR-50 monoclonal antibody. J Neurosci (1997) 17:23&#x2013;31. doi:&#xa0;10.1523/JNEUROSCI.17-01-00023.1997</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.17-01-00023.1997</ArticleId><ArticleId IdType="pmc">PMC6793694</ArticleId><ArticleId IdType="pubmed">8987733</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, et al. . Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell (1999) 97:689&#x2013;701. doi:&#xa0;10.1016/s0092-8674(00)80782-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(00)80782-5</ArticleId><ArticleId IdType="pubmed">10380922</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissir F, Goffinet AM. Reelin and brain development. Nat Rev Neurosci (2003) 4:496&#x2013;505. doi:&#xa0;10.1038/nrn1113</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1113</ArticleId><ArticleId IdType="pubmed">12778121</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci (2006) 7:850&#x2013;9. doi:&#xa0;10.1038/nrn2009</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2009</ArticleId><ArticleId IdType="pubmed">17053810</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Massaro CM, Palop JJ, Thwin MT, Yu G-Q, Bien-Ly N, et al. . Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with alzheimer&#x2019;s disease. J Neurosci (2007) 27:2727&#x2013;33. doi:&#xa0;10.1523/JNEUROSCI.3758-06.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3758-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672562</ArticleId><ArticleId IdType="pubmed">17360894</ArticleId></ArticleIdList></Reference><Reference><Citation>Marckx AT, Fritschle KE, Calvier L, Herz J. Reelin changes hippocampal learning in aging and alzheimer&#x2019;s disease. Behav Brain Res (2021) 414:113482. doi:&#xa0;10.1016/j.bbr.2021.113482</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2021.113482</ArticleId><ArticleId IdType="pmc">PMC8483237</ArticleId><ArticleId IdType="pubmed">34333070</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina Y, Enose-Akahata Y, Hammoud DA, Videckis AJ, Narpala SR, O'Connell SE, et al. . Deep phenotyping of neurologic postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm (2023) 10(4):e200097. doi:&#xa0;10.1212/NXI.0000000000200097</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200097</ArticleId><ArticleId IdType="pmc">PMC10162706</ArticleId><ArticleId IdType="pubmed">37147136</ArticleId></ArticleIdList></Reference><Reference><Citation>Samama B, Boehm N. Reelin immunoreactivity in lymphatics and liver during development and adult life. Anat Rec A Discovery Mol Cell Evol Biol (2005) 285:595&#x2013;9. doi:&#xa0;10.1002/ar.a.20202</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ar.a.20202</ArticleId><ArticleId IdType="pubmed">15912522</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutter S, Xie S, Tatin F, Makinen T. Smooth muscle-endothelial cell communication activates reelin signaling and regulates lymphatic vessel formation. J Cell Biol (2012) 197:837&#x2013;49. doi:&#xa0;10.1083/jcb.201110132</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201110132</ArticleId><ArticleId IdType="pmc">PMC3373399</ArticleId><ArticleId IdType="pubmed">22665518</ArticleId></ArticleIdList></Reference><Reference><Citation>Khialeeva E, Carpenter EM. Nonneuronal roles for the reelin signaling pathway. Dev Dyn (2017) 246:217&#x2013;26. doi:&#xa0;10.1002/dvdy.24462</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.24462</ArticleId><ArticleId IdType="pubmed">27739126</ArticleId></ArticleIdList></Reference><Reference><Citation>Racetin A, Juri&#x107; M, Filipovi&#x107; N, &#x160;oli&#x107; I, Kosovi&#x107; I, Glavina Durdov M, et al. . Expression and localization of DAB1 and reelin during normal human kidney development. Croat Med J (2019) 60:521&#x2013;31. doi:&#xa0;10.3325/cmj.2019.60.521</Citation><ArticleIdList><ArticleId IdType="doi">10.3325/cmj.2019.60.521</ArticleId><ArticleId IdType="pmc">PMC6952895</ArticleId><ArticleId IdType="pubmed">31894918</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelletto A, Allan HE, Crescente M, Schneider E, Bussani R, Ali H, et al. . SARS-CoV-2 spike protein activates TMEM16F-mediated platelet procoagulant activity. Front Cardiovasc Med (2022) 9:1013262. doi:&#xa0;10.3389/fcvm.2022.1013262</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.1013262</ArticleId><ArticleId IdType="pmc">PMC9845929</ArticleId><ArticleId IdType="pubmed">36684586</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeber EJ, Beffert U, Jones C, Christian JM, Forster E, Sweatt JD, et al. . Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem (2002) 277:39944&#x2013;52. doi:&#xa0;10.1074/jbc.M205147200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M205147200</ArticleId><ArticleId IdType="pubmed">12167620</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, Weeber EJ, Durudas A, Qiu S, Masiulis I, Sweatt JD, et al. . Modulation of synaptic plasticity and memory by reelin involves differential splicing of the lipoprotein receptor Apoer2. Neuron (2005) 47:567&#x2013;79. doi:&#xa0;10.1016/j.neuron.2005.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.07.007</ArticleId><ArticleId IdType="pubmed">16102539</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong C, Wang T-W, Huang HS, Parent JM. Reelin regulates neuronal progenitor migration in intact and epileptic hippocampus. J Neurosci (2007) 27:1803&#x2013;11. doi:&#xa0;10.1523/JNEUROSCI.3111-06.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3111-06.2007</ArticleId><ArticleId IdType="pmc">PMC6673551</ArticleId><ArticleId IdType="pubmed">17314278</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu S, Renfro A, Quattrocchi CC, Sheldon M, D&#x2019;Arcangelo G. Reelin promotes hippocampal dendrite development through the VLDLR/ApoER2-Dab1 pathway. Neuron (2004) 41:71&#x2013;84. doi:&#xa0;10.1016/s0896-6273(03)00819-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0896-6273(03)00819-5</ArticleId><ArticleId IdType="pubmed">14715136</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu S, Yabut O, D&#x2019;Arcangelo G. The reelin signaling pathway promotes dendritic spine development in hippocampal neurons. J Neurosci (2008) 28:10339&#x2013;48. doi:&#xa0;10.1523/JNEUROSCI.1917-08.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1917-08.2008</ArticleId><ArticleId IdType="pmc">PMC2572775</ArticleId><ArticleId IdType="pubmed">18842893</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, et al. . Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol (2013) 33:67&#x2013;75. doi:&#xa0;10.1161/ATVBAHA.112.300569</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.112.300569</ArticleId><ArticleId IdType="pubmed">23117656</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, S&#xe1;daba JR, et al. . The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail (2015) 3:59&#x2013;67. doi:&#xa0;10.1016/j.jchf.2014.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2014.08.002</ArticleId><ArticleId IdType="pubmed">25458174</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Mart&#xed;nez E, Calvier L, Fern&#xe1;ndez-Celis A, Rousseau E, Jurado-L&#xf3;pez R, Rossoni LV, et al. . Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension (2015) 66:767&#x2013;75. doi:&#xa0;10.1161/HYPERTENSIONAHA.115.05876</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.115.05876</ArticleId><ArticleId IdType="pubmed">26238446</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvier L, Legchenko E, Grimm L, Sallmon H, Hatch A, Plouffe BD, et al. . Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Heart (2016) 102:390&#x2013;6. doi:&#xa0;10.1136/heartjnl-2015-308365</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2015-308365</ArticleId><ArticleId IdType="pubmed">26869635</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Mart&#xed;nez E, Calvier L, Rossignol P, Rousseau E, Fern&#xe1;ndez-Celis A, Jurado-L&#xf3;pez R, et al. . Galectin-3 inhibition prevents adipose tissue remodelling in obesity. Int J Obes (Lond) (2016) 40(6):1034&#x2013;8. doi:&#xa0;10.1038/ijo.2016.19</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijo.2016.19</ArticleId><ArticleId IdType="pubmed">26853916</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Martinez E, Ibarrola J, Calvier L, Fernandez-Celis A, Leroy C, Cachofeiro V, et al. . Galectin-3 blockade reduces renal fibrosis in two normotensive experimental models of renal damage. PloS One (2016) 11:e0166272. doi:&#xa0;10.1371/journal.pone.0166272</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0166272</ArticleId><ArticleId IdType="pmc">PMC5102450</ArticleId><ArticleId IdType="pubmed">27829066</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Mart&#xed;nez E, Ibarrola J, Fern&#xe1;ndez-Celis A, Calvier L, Leroy C, Cachofeiro V, et al. . Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats. J Hypertens (2018) 36:368&#x2013;76. doi:&#xa0;10.1097/HJH.0000000000001545</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000001545</ArticleId><ArticleId IdType="pubmed">28858976</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervantes-Alvarez E, la Rosa NL, la Mora MS, Valdez-Sandoval P, Palacios-Jimenez M, Rodriguez-Alvarez F, et al. . Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients. Sci Rep (2022) 12:1856. doi:&#xa0;10.1038/s41598-022-05968-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-05968-4</ArticleId><ArticleId IdType="pmc">PMC8813958</ArticleId><ArticleId IdType="pubmed">35115644</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvier L, K&#xf6;k&#xe9;ny G, Martinez-Martinez E. Editorial: new advances in cardiorenal syndrome. Front Cardiovasc Med (2022) 9:976846. doi:&#xa0;10.3389/fcvm.2022.976846</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.976846</ArticleId><ArticleId IdType="pmc">PMC9331892</ArticleId><ArticleId IdType="pubmed">35911551</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>